Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
The role for S-carboxymethylcysteine (carbocisteine) in the management of chronic obstructive pulmonary disease Hooper C; Calvert JInt J Chron Obstruct Pulmon Dis 2008[]; 3 (4): 659-69Prescription of mucoactive drugs for chronic obstructive pulmonary disease (COPD) is increasing. This development in clinical practice arises, at least in part, from a growing understanding of the important role that exacerbation frequency, systemic inflammation and oxidative stress play in the pathogenesis of respiratory disease. S-carboxymethylcysteine (carbocisteine) is the most frequently prescribed mucoactive agent for long-term COPD use in the UK. In addition to its mucoregulatory activity, carbocisteine exhibits free-radical scavenging and anti-inflammatory properties. These characteristics have stimulated interest in the potential that this and other mucoactive drugs may offer for modification of the disease processes present in COPD. This article reviews the pharmacology, in vivo and in vitro properties, and clinical trial evidence for carbocisteine in the context of guidelines for its use and the current understanding of the pathogenic processes that underlie COPD.|Animals[MESH]|Anti-Inflammatory Agents/administration & dosage/adverse effects/*therapeutic use[MESH]|Carbocysteine/administration & dosage/adverse effects/*analogs & derivatives/*therapeutic use[MESH]|Clinical Trials as Topic[MESH]|Drug Administration Schedule[MESH]|Expectorants/administration & dosage/adverse effects/*therapeutic use[MESH]|Free Radical Scavengers/administration & dosage/adverse effects/*therapeutic use[MESH]|Humans[MESH]|Oxidative Stress/drug effects[MESH]|Practice Guidelines as Topic[MESH]|Pulmonary Disease, Chronic Obstructive/*drug therapy/metabolism[MESH]|Treatment Outcome[MESH] |
